Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-06
2005-12-06
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S453000, C514S619000
Reexamination Certificate
active
06972298
ABSTRACT:
The present invention provides a method of treating or preventing neutrophil chemotaxis. Specifically, the present invention provides a method of treating or preventing neutrophil migration by administering to a patient a MEK inhibitor.
REFERENCES:
patent: 5525625 (1996-06-01), Bridges et al.
patent: 5962265 (1999-10-01), Norris et al.
patent: 6251943 (2001-06-01), Barrett et al.
patent: 6440966 (2002-08-01), Barrett et al.
patent: 2003/0060469 (2003-03-01), Ludwig et al.
patent: WO 98/37881 (1998-09-01), None
patent: WO 99/01421 (1999-01-01), None
patent: WO 99/01426 (1999-01-01), None
patent: WO 99/34792 (1999-07-01), None
patent: WO 00/35435 (2000-06-01), None
patent: WO 00/35436 (2000-06-01), None
patent: WO 00/37141 (2000-06-01), None
patent: WO 00/40235 (2000-07-01), None
patent: WO 00/40237 (2000-07-01), None
patent: WO 01/05392 (2001-01-01), None
patent: WO 02/06213 (2002-01-01), None
patent: WO 02/069960 (2002-09-01), None
patent: WO 02/076496 (2002-10-01), None
P. J. Barnes, “Future Advances in COPD Therapy”, Respiration, vol. 68, pp 441-448 (2001).
Database WPI, Section Ch, Week 200213, Derwent Publications, Ltd., London, GB, An (2002)097426 Abstract Only.
T. Sasaki, et al., “Function of P13kGamma in Thymocyte Development, T Cell Activation, and Neutrophil Migration”, Science, vol. 287, P. 1040-1046 (2000).
J. C. Lee, et al., “Inhibition of p38 MAP Kinase as a Therapeutic Strategy”, Immunopharmacology, vol. 47, p. 185-201 (2000).
P. Scapini, et al., “The neutrophil as a cellular source of chemokines”, Immunol. Rev., vol. 177, p. 195-203 (2000).
C. R. Mackay, “Chemokines: Immunology's high impact factors”, Nat. Immunol. vol. 2(2), p. 95-101 (2001).
D. Rossi, et al., “The biology of chemokines and their receptors”, Ann. Rev. Immunol., vol. 18, p. 217-242 (2000).
N.T. Luu, et al., “Differential ability of exogenous chemotactic agents to disrupt transendothelial migration of flowing neutrophils”, J. Immunol. vol. 164, p. 5961-5969 (2000).
E. Sato, et al., “Reactive nitrogen and oxygen species attenuate interleukin-8-induced neutrophil chemotactic activity, in vitro”, J. Biol. Chem., vol. 275, p. 10826-10830 (2000).
M.D. Becker, et al., “Reduced leukocyte migration, but normal rolling and arrest, in interleukin-8-receptor homologue knockout mice”, Invest. Opthalmol. Vis. Sci., vol. 41, p. 1812-1817 (2000).
O. Tabary, et al., “High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content”, J. Immunol., vol. 164, p. 3377-3384 (2000).
R.A. Dumont, et al. “Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits”, Infect. Immun., vol. 68, p. 5756-5763 (2000).
A. Ben-Baruch, et al., “Interleukin-8 receptor beta: The role of the carboxy terminus in signal transduction”, J. Biol. Chem., vol. 270, p. 9121-9128 (1995).
V. Shyamala, et al., “Interleukin-8 Receptors R1 and R2 Activate Mitogen-Activated Protein Kinases and Induce c-fos, Independent of Ras and Raf-1 in Chinese Hamster Ovary Cells”, Biochemistry, vol. 37, p. 15918-15924 (1998).
R.M. Richardson, et al., “Multiple signaling pathways of human interleukin-8 receptor A. Independent regulation by phosphorylation”, J. Biol. Chem., vol. 273, p. 10690-10695 (1998).
C, Knall, et al., “Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracllular signal-regulated kinase and p38 mitogen-activated protein kinases”, Proc. Natl. Acad. Sci., vol. 94, p. 3052-3057 (1997).
J.S. Sebolt-Leopold, et al., “Blockade of the Map kinase pathway suppresses growth of colon tumors in vivo”, Nat. Med., vol. 5, p. 810-816 (1999).
C. Knall, et al., Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils, J. Biol. Chem., vol. 271, p. 2832-2838 (1996).
Baragi Vijaykumar M.
Devalaraja Madhav Narasimha
Low Joseph Edwin
Padgaonkar Vaishalee A.
Butterfield Garth
Henley III Raymond J.
Richardson Peter C.
Warner-Lambert & Company
LandOfFree
Method of treating or inhibiting neutrophil chemotaxis by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating or inhibiting neutrophil chemotaxis by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating or inhibiting neutrophil chemotaxis by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3505972